Notícias

CVS Health's strong cash generation, higher operating cash flow outlook and disciplined capital deployment support continued deleveraging in 2026.

CVS Health (CVS) recently raised its 2026 adjusted earnings per share guidance to a range of US$7.90 to US$8.10 and outlined plans to invest US$20 billion in healthcare technology and data infrastructure. Those guidance comments and investment plans have landed in a stock that has already seen momentum pick up. CVS Health’s 1 day share price return of 3.93% and 7 day return of 5.06% come after a 30 day decline of 6.54%, while the year to date share price return of 21.80% and 1 year total...

Wall Street is warming to the prospects of the healthcare giant.

Its deepest fall inside a market shock is not its deepest fall, and that gap is what a holder should size for.

Consensus knocks a quarter off the health insurer's earnings multiple over two years, part of it measurement, and almost none of it from selling more coverage.

Sen. Elizabeth Warren (D-Mass.) warned that growing corporate consolidation is giving a small group of powerful companies and CEOs outsized influence over Americans’ everyday choices, urging regulators to block mega-mergers. Warren Targets Corporate Consolidation On Saturday, in a post on...

Weight loss drug consumers get a Medicare cost break, but it has a deadline.

UnitedHealth Group's stronger six-month return, improving UnitedHealthcare and Optum results and attractive valuation make it the better buy.

The healthcare giant's shares have pulled back more than 12% over the past month.

Its market-shock drawdowns have been ordinary in depth, and some of its longest waits back to the old high came after falls the index barely noticed.

Cigna, Molina, and at least 10 other carriers will stop selling Obamacare plans, affecting hundreds of thousands of enrollees in more than 20 states

The healthcare giant sent a fortune back to its owners, but the market yawned. Here’s the real accounting of what that cash bought, and what it didn't.

A powerful healthcare business model is facing fresh political pressure

CVS Health carries strong pharmacy momentum into H2 2026, with rising prescription volume, Rite Aid gains and higher profit.

Both CVS and Intel delivered real turnaround results in 2026, then both stocks got punished for very different reasons. For a retiree drawing income from a portfolio, one of those reasons matters far more than the other.

CVS Health recently announced that long-serving director Larry M. Robbins resigned from its board in August 2026 and that Teresa Heitsenrether, Executive Vice President and Chief Data & Analytics Officer at JPMorgan Chase, will join as an independent director in November 2026. Alongside this governance shift, CVS Pharmacy launched its Home Team Heroes youth soccer initiative, underlining the company’s emphasis on community engagement and brand building at a time when analysts are focused on...

They aren't the most prominent names in the GLP-1 space, but they are worth a second look.

CVS Health has had an impressive run over the past six months as its shares have beaten the S&P 500 by 12.8%. The stock now trades at $93.94, marking a 23.3% gain. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.

DHR's Biotechnology segment grows as China demand, bioprocessing and improving discovery markets offset regional headwinds.

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

Medicare's improvement is real but not a turn in cost trend, while commercial costs keep running higher and the margin fix there has slipped again.

One of the pharmacy operator's segments is doing particularly well.

The healthcare giant is wrestling with costs in one part of its business, and the stock's recent dip has investors wondering if this is the moment to step in.

Mark Cuban says AI will never replace radiologists, and his reasoning has nothing to do with capability. The real disruption, he argues, targets a different layer of medicine entirely, one worth hundreds of billions in enterprise value at some of the biggest names in healthcare.

The gap between its revenue multiple and its cash multiple is margin, and the company is spending it on purpose.

Walmart beat revenue estimates and raised its full-year outlook, yet its stock still fell as investors zeroed in on one ugly number. The real reason behind that miss has nothing to do with shoppers tightening their belts.

CVS Health stock has delivered a 58.7% return over the past three years, yet its current valuation checks still lean toward the shares looking inexpensive on several fronts. Recent headlines around growth in healthcare services and legal disputes create a mixed backdrop for anyone trying to work out what that price implies. Over the last three years CVS Health has returned 58.7%, which puts recent swings into context and suggests investors have already re-rated the stock...

With stocks in bullish mode it’s a good time to run Barchart’s Bull Call Spread Screener.

CVS Health (CVS) is back in focus after a board reshuffle and fresh financial milestones. Recent earnings, guidance and management changes give investors new information to weigh around the stock’s current pricing. See our latest analysis for CVS Health. CVS Health’s recent board reshuffle and raised earnings guidance have come alongside mixed momentum, with the 1 month share price return down 11.69% but year to date share price return at 18.45%, and a 1 year total shareholder return of...

CVS Health (NYSE: CVS) announced that board member Larry M. Robbins has resigned from the Board of Directors. The company has appointed Teresa Heitsenrether, a senior executive from JPMorgan Chase with deep experience in data and analytics, to the CVS Health board. The board change highlights CVS Health's focus on technology, data and digital healthcare capabilities at the governance level. For investors who view data driven healthcare as a wider theme rather than solely a CVS Health story,...